ASSESS AND ADDRESS RISK OF CARDIOVASCULAR DISEASE

Similar documents
Goals for Today s Session Upon completion of this activity, participants should be able to return to their practices with ideas to improve adherence

Blue Shield Participation

Getting to the Heart of the Matter: Hypertension and The Million Hearts Initiative

Improving Type 2 Diabetes Therapy Compliance and Persistence in the Kingdom of Saudi Arabia

Best Practices in Cardiac Care: Getting with the Guidelines

Supplementary Online Content

Measure Up Pressure Down. Scott Flinn MD Fritz Steen RN

Lipid Management 2013 Statin Benefit Groups

Dyslipidemia and Combination Therapy: A Framework for Clinical Decision Making

Agenda. Immunization Registry Reporting in Community Health Centers. Presented by: Ben Pierson Program Manager Health Information Exchange

Diabetes Care begins with Diabetes Prevention. Neha Sachdev, MD Janet Williams, MA

August 2015 Campaign Updates

Engaging patients and providers with the right information, at the right time, to do the right thing

Improving Type 2 Diabetes Therapy Adherence and Persistence in Mexico

2014 Update in Medicine Update in Cholesterol Management. Donald L. Lappé MD, FACC, FAHA October 31, 2014

Preventing 1 Million Heart Attacks and Strokes by 2022

Improving Type 2 Diabetes Therapy Compliance and Persistence in Brazil

Medical Apps for Cardiology Uses. There s an App for That!

Drug Coverage for EpiPens to Change July 1

A Case Study on Visual Analytics for Optimizing Drug Duplicate Alerts in a Medication Clinical Decision Support System

When Statins Aren t Enough: Appropriate Therapies for High-Risk Patients with Diabetes

Measuring Hypertension Control. Reporting Methods for Measure Up/Pressure Down

4/24/15. AHA/ACC 2013 Guideline Key Points

Cholesterol Management Roy Gandolfi, MD

CMMI Project: San Diego A Heart Attack and Stroke Free Zone. Parag Agnihotri, MD Chair of the Healthcare Committee

Calculating Risk for Primary Prevention of Cardiovascular Disease (CVD)

2/10/2016. Perspectives on the 2013 ACC/AHA Cholesterol Guidelines. Disclosures. ATP-III Update 2004

MEDICATION ADHERENCE: WE DIDN T ASK & THEY DIDN T TELL

Aha blood pressure guidelines 2016 chart. Pinni Meedha Mojutho Ammanu Dengina Koduku Part 1 Kama Kathalu

Long-Term Management Of the ACS Patient: State-of-the-Art. Kim Newlin, CNS, NP-C, FPCNA Sutter Roseville Medical Center Roseville, CA

Team-Based Decision Support in Diabetes Outcomes and Costs

Deep Dive into Contemporary Cholesterol Management. Kim Allan Williams, Sr., MD, FACC Pamela B. Morris, MD, FACC 7 October 2016 Mexico City

2014/10/20. Management of Lipid Disorders Eric Klug Sunninghill, Sunward Park and CM JHB Academic Hospitals

2017 Diabetes. Program Evaluation. Our mission is to improve the health and quality of life of our members

Steps Against Recurrent Stroke (STARS)

ACC/AHA GUIDELINES ON LIPIDS AND PCSK9 INHIBITORS

Measure Owner Designation. AMA-PCPI is the measure owner. NCQA is the measure owner. QIP/CMS is the measure owner. AMA-NCQA is the measure owner

Achieving Cholesterol Management Goals: Identifying Clinician-Centered Challenges to Optimal Patient Care

New Models of Evidence Generation and Cancer Care Delivery: Distance Medicine Technologies

2013 ACC/AHA Guidelines on the Assessment of Atherosclerotic Cardiovascular Risk: Overview and Commentary

Improving Type 2 Diabetes Therapy Adherence and Persistence in the United States

Preventing and Addressing Chronic Disease. Tim Nikolai, Sr. Community Health Director

Driving Outcomes By Scaling Population Health Management

2014 Evidence-Based HTN Guideline: Preliminary Data from AMGA s Anceta Collaborative

MedStar St. Mary s Hospital Pioneers In Quality Presentation. Presenter: Elizabeth Ballard, MSN, RN and Dawn Yeitrakis MS, RN, CEN

Treating Hypertension in 2018: What Makes the Most Sense Today?

PDMP Tools to Identify Red Flag Situations

Tobacco screening and follow-up if positive for tobacco use

Costing report: Lipid modification Implementing the NICE guideline on lipid modification (CG181)

American Diabetes Association 2018 Guidelines Important Notable Points

Donna Amundson, RN, BSN, CDE Director of the Sanford Diabetes Center Bismarck, ND

Observations on US CVD Prevention Guidelines. Donald M. Lloyd-Jones, MD ScM FACC FAHA

Leverage Healthcare Technology Applications to Improve Primary Nonadherence.

Know Your Number Aggregate Report Comparison Analysis Between Baseline & Follow-up

Target: BP Overview with Lake Superior QIN Wednesday, February 22, :00 PM 1:00 PM CST

Cost-Effective Process to Improve Drug Adherence for Medicare 5-Star

Crossing The Quality Chasm: Cardiovascular Care

Measure Up/Pressure Down Medical Group Success

NQF Members NQF Staff Voting Draft Report: NQF-Endorsed Measures for Cardiovascular DA: October 17, 2016

2013 Cholesterol Guidelines. Anna Broz MSN, RN, CNP, AACC Adult Certified Nurse Practitioner North Ohio Heart, Inc.

Measure Up / Pressure Down: Improving Blood Pressure Control in Washington, DC

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

Physicians and QIOs Improving Health Outcomes Together. AHQA 2014 Annual Meeting

Pamela B. Morris, MD, FACC, FAHA, FASPC, FNLA

Update on Lipid Management in Cardiovascular Disease: How to Understand and Implement the New ACC/AHA Guidelines

Steps Against Recurrent Stroke (STARS)

Disclosure. I have no relevant financial relationships with commercial interests to disclose American Medical Association. All rights reserved.

Preventive Cardiology Scientific evidence

Health Care Systems Research Network (HCSRN) Conference April 12, 2018 Minneapolis, MN

Improving Medication Adherence through Collaboration between Colleges of Pharmacy and Community Pharmacies

A COMPREHENSIVE APPROACH TO MANAGING DIABETES

High-quality diabetes care can

Diagnosis and Management of Type 2 Diabetes Mellitus in Adults

ACC/AHA Guidelines Bulls-eyes and Misses

Cardio-Protective Medication Bundle. Louis H. Carter II, PharmD.

Case Studies The Role of Non-Statin Therapies for LDL-C Lowering in the Management of ASCVD Risk

Primary Prevention of Cardiovascular Disease (CVD) Events with Statins. 1 Primary Prevention of Cardiovascular Disease (CVD) Events with Statins

CARD 1: What is AFib and how does it relate to stroke? Talk to your patient about their condition and its connection to stroke.

2013 Cholesterol Guidelines. Anna Broz MSN, RN, CNP, AACC Cer=fied Adult Nurse Prac==oner North Ohio Heart, Inc.

NEW GUIDELINES FOR CHOLESTEROL

Patient Education. intermountainhealthcare.org/diabetes. BG Tracker. for people with diabetes MONITORING BLOOD GLUCOSE

2015 Healthy Heart. Program Evaluation. Our mission is to improve the health and quality of life of our members

CONVERSATION STARTERS: ENGAGING YOUR PATIENTS AT PICK UP JULY 12, :00 2:30 PM

9/18/2017 DISCLOSURES. Consultant: RubiconMD. Research: Amgen, NHLBI OUTLINE OBJECTIVES. Review current CV risk assessment tools.

Effective Strategies to Help Customers Use Their EHR to Improve Quality of Care

Purpose: To establish a guideline in order to reduce ASCVD risk based the four identified statin benefit groups

BACKGROUND: Formal networks of practices are well-established platforms for learning and sharing pragmatic lessons about clinical practice to improve

HYPERLIPIDEMIA IN THE OLDER POPULATION NICOLE SLATER, PHARMD, BCACP AUBURN UNIVERSITY, HARRISON SCHOOL OF PHARMACY JULY 16, 2016

= AUDIO. Managing Diabetes for Improved Cardiovascular Health. An Important Reminder. Mission of OFMQ 8/18/2015. Jimmi Norris MS, RN, CDE

CORONARY ARTERY DISEASE (CAD) MEASURES GROUP OVERVIEW

Guidelines on cardiovascular risk assessment and management

Disclosure. No relevant financial relationships. Placebo-Controlled Statin Trials

Clinical Implications of Revised Pooled Cohort Equations for Estimating Atherosclerotic Cardiovascular Disease Risk

The MetroHealth System. Creating the HIT Organizational Culture at MetroHealth. Creating the HIT Organizational Culture

MU - Selection & Configuration of Measures

Managing Dyslipidemia and ASCVD Risk: Confusion, Controversy Consensus

Managing Chronic Kidney Disease: Reducing Risk for CKD Progression

9/25/15. Pharmacy Quality Measures: Financial Support. Learning Objectives. Speaker Disclosure. Access to Preferred Networks and Clinical Performance

CMS-3311-P 100 TABLE 6: MEANINGFUL USES OBJECTIVES AND MEASURES FOR 2015 THROUGH 2017

Financial Disclosures. Coronary Artery Calcification. Objectives. Coronary Artery Calcium 6/6/2018. Heart Disease Statistics At-a-Glace 2017

Transcription:

ASSESS AND ADDRESS RISK OF CARDIOVASCULAR DISEASE Heart diseases and stroke are the top causes of death and disability among people with Type 2 diabetes. In fact, at least 65 percent of people with diabetes die from some form of heart disease or stroke. To reverse these trends, care teams must assess risk of cardiovascular disease for people with Type 2 diabetes and intervene in order to prevent these major health events. TIPS TO INCORPORATE CARDIOVASCULAR RISK ASSESSMENT n Use the ACC/AHA ASCVD Risk Calculator (refer to Appendix E: Suggested Readings for a link) for all patients with Type 2 diabetes over 40 years old annually, but including those who are newly diagnosed with the condition. n Develop a workflow to facilitate ease of adoption. This workflow may incorporate: Inclusion of point-of-care alerts, Care teams systematically evaluate each patient s risk for cardiovascular disease, using a trusted risk assessment tool. For patients at risk, treatment plans include primary and secondary prevention in accordance with American Diabetes Association (ADA) recommendations for lifestyle, lipid-lowering and antihypertensive medications, and aspirin. Delegation of this responsibility (e.g., to a medical assistant or care coordinator), Development of automated tools built into the EHR, and Utilization monitoring of these tools (e.g., Did a point-of-care alert appear and was statin ordered, if appropriate? Did medication reconciliation include statin adherence over 80%?). n Ensure the results are entered into the EHR and/or your diabetes registry in a discrete, searchable field. n Educate clinicians and care team members about the importance of cardiovascular risk assessment for patients with Type 2 diabetes, the approved workflow, and appropriate management per your organization s treatment algorithms (refer to Adopt Treatment Algorithm plank). n Develop or adopt treatment guidelines that include use of moderate- or high-intensity statins, lifestyle changes, antihypertensive medications, and aspirin for at-risk patients. n Establish a process to assess medication adherence such as patient questionnaires, selfreports, pill counts, and pharmacy refills. n Offer patient education materials and selfmanagement tools that are culturally appropriate and accessible to audiences with low literacy. n Monitor use of the risk calculator and adherence to the workflow and report back to the Accountable Diabetes Team at your organization (refer to Build an Accountable Diabetes Team plank). n Leverage the work previously completed in your organization with Measure Up/Pressure Down or other related efforts. ASSESS AND ADDRESS RISK OF CARDIOVASCULAR DISEASE 73

TOOL: CARDIOVASCULAR DISEASE ALGORITHM INTERMOUNTAIN HEALTHCARE Used with permission from Intermountain Healthcare. Copyright 2001-2015, Intermountain Healthcare. CAMPAIGNTOOLKIT

INTERMOUNTAIN HEALTHCARE ASSESS AND ADDRESS RISK OF CARDIOVASCULAR DISEASE TOOL: CARDIOVASCULAR DISEASE ALGORITHM (CONTINUED) 75

TOOL: CHOLESTEROL ALGORITHM INTERMOUNTAIN HEALTHCARE Used with permission from Intermountain Healthcare. Copyright 2001-2015, Intermountain Healthcare. CAMPAIGNTOOLKIT

INTERMOUNTAIN HEALTHCARE ASSESS AND ADDRESS RISK OF CARDIOVASCULAR DISEASE TOOL: CHOLESTEROL ALGORITHM (CONTINUED) 77

TOOL: HYPERTENSION ALGORITHM INTERMOUNTAIN HEALTHCARE Used with permission from Intermountain Healthcare. Copyright 2001-2015, Intermountain Healthcare. CAMPAIGNTOOLKIT

INTERMOUNTAIN HEALTHCARE ASSESS AND ADDRESS RISK OF CARDIOVASCULAR DISEASE TOOL: HYPERTENSION ALGORITHM (CONTINUED) 79

TOOL: ADULT LIPID GUIDELINES SUTTER HEALTH CAMPAIGNTOOLKIT

SUTTER HEALTH ASSESS AND ADDRESS RISK OF CARDIOVASCULAR DISEASE TOOL: ADULT LIPID GUIDELINES (CONTINUED) 81

TOOL: ADULT LIPID GUIDELINES (CONTINUED) SUTTER HEALTH CAMPAIGNTOOLKIT

SUTTER HEALTH ASSESS AND ADDRESS RISK OF CARDIOVASCULAR DISEASE TOOL: ADULT LIPID GUIDELINES (CONTINUED) 83

TOOL: ADULT LIPID GUIDELINES (CONTINUED) SUTTER HEALTH CAMPAIGNTOOLKIT